Augma

Augma Biomaterials is a dynamic, innovative company, focused on developing bone substitutes for bone augmentation in maxillofacial surgery.The activity of the company is focused on two main categories:. Development of novel augmentative products that are based on many years of personal experience and consider the challenges which clinicians in the dental field face. Augma Biomaterials is devoted to the development, production, and marketing of natural mineral bone substitutes for the dental market. The company focuses its activity on the development of innovative materials required for bone augmentation, based on a novel technology, scientific knowledge, and extensive research. Amos Yahav, D.M.D, is the Chairman of the Board and Founder of Augma Biomaterials Ltd. The company continues to operate under these principles in order to bring further developments and innovation to the dental field, all for the benefit of the clinician and the patient. Bond Apatite® is a composite graft, composed of 2/3 biphasic calcium sulfate cement matrix’s and 1/3 HA granules in a controlled particle size distribution, intended to fill or augment a large diversity of osseous defects.